GlassScriptPhysician profile
Nancy C Boss
NPI 1386163244
$9,883.36
in general payments reported to CMS, 2019-2025
38 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,827 · 2022: $188 · 2023: $3,031 · 2024: $3,450 · 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,041 · Travel and Lodging: $2,722 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,041.30 |
| Travel and Lodging | $2,721.65 |
| Education | $105.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,019.18 | 2023-2024 | Percept PC Brainsense, Intellis Adaptivestim |
| Boston Scientific Corporation | $1,810.60 | 2021 | |
| Livanova USA, INC. | $1,610.75 | 2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $1,007.11 | 2022-2025 | |
| Emd Serono, INC. | $415.31 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $371.66 | 2023-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $320.88 | 2024-2025 | |
| Ucb, INC. | $305.25 | 2023-2025 | Briviact, Rystiggo, Zilbrysq |
| Lilly USA, LLC | $208.49 | 2023-2025 | Emgality, Kisunla, Amyvid |
| Argenx US, INC. | $187.87 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $184.64 | 2023-2025 | Xcopri |
| Jazz Pharmaceuticals INC. | $180.57 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $171.31 | 2022 | |
| Alexion Pharmaceuticals, INC. | $152.49 | 2024-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $144.89 | 2023-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $99.40 | 2023-2024 | Purified Cortrophin Gel |
| Amylyx Pharmaceuticals, INC. | $93.86 | 2023-2024 | Relyvrio |
| Tanabe Pharma America, INC. | $78.37 | 2024 | |
| Biogen, INC. | $73.18 | 2023-2025 | Vumerity, Skyclarys, Avonex |
| Genzyme Corporation | $44.96 | 2024-2025 | |
| Acorda Therapeutics, INC | $38.55 | 2023 | Inbrija, Ampyra |
| Teva Pharmaceuticals USA, INC. | $37.09 | 2023-2025 | Austedo Xr, Austedo Xr |
| Neurelis, INC. | $29.90 | 2024 | Valtoco |
| Axsome Therapeutics, INC. | $29.08 | 2023 | Sunosi |
| Lundbeck LLC | $27.74 | 2023-2024 | Vyepti |
| Averitas Pharma INC. | $25.19 | 2023 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $25.08 | 2024 | Hyqvia |
| Abbott Laboratories | $23.97 | 2023 | Infinity |
| Amneal Pharmaceuticals LLC | $23.33 | 2023 | Rytary |
| Otsuka America Pharmaceutical, INC. | $19.06 | 2025 | Rexulti |
| Banner Life Sciences, LLC | $17.94 | 2024 | |
| Corium, LLC | $17.66 | 2023 | Adlarity |
| Ge Healthcare | $16.37 | 2024 | |
| Collegium Pharmaceutical, INC. | $15.98 | 2021 | |
| Sumitomo Pharma America, INC. | $14.61 | 2024 | Aptiom |
| Genentech USA, INC. | $13.95 | 2023 | Ocrevus |
| Kyowa Kirin, INC. | $13.64 | 2023 | Nourianz |
| Mallinckrodt Hospital Products INC. | $13.45 | 2023 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Boss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.